Cross-resistance of cisplatin selected cells to anti-microtubule agents: Role of general survival mechanisms.

ABSTRACT: Although the first line of therapy for epithelial ovarian cancer typically consists of taxane-platinum combination therapy, many patients develop a platinum-resistant tumor within a year. Several previous studies have looked at this cross-resistance between cisplatin and anti-microtubule drugs, but their findings have been somewhat conflicting. Here, we developed cisplatin-resistant cell lines that are resistant to low and high levels of cisplatin and explored the effects of three anti-microtubule drugs (paclitaxel, vincristine, and colchicine) on the parental and cisplatin-resistant cells. We found that cells resistant to lower levels of cisplatin were no more resistant to anti-microtubule drugs than parental cells, while cells that were resistant to higher levels of cisplatin had a subpo

SUBMITTER: Patel RP 

PROVIDER: S-EPMC7586247 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature